Global Longlife (543520)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Hospital industry has long-term demand tailwinds in India, though this is not company-specific.
• Small market cap of ₹33 Cr could offer high operating leverage if revenue ever returns.
• Trading at the upper end of its 52-week range indicates speculative market interest, providing exit liquidity.
• Listed platform gives access to capital markets for potential revival, if management acts.

Concerns

• Latest quarter sales are ₹0 Cr with -100% sales growth; the company is generating no revenue.
• Net loss of ₹1 Cr and profit growth of -206.45% show deteriorating losses.
• ROCE of -13.69% and Piotroski F-score of 2/9 reflect poor capital efficiency and financial stress.
• No earnings, book value, dividend, or debt/equity disclosure makes valuation and safety assessment impossible.

AI Analysis

Let me begin with what I look for: a business I understand, with durable earnings, a moat, and a sound balance sheet. Global Longlife fails all three. This hospital posted zero sales in the latest quarter, and sales growth is -100%. A hospital with no revenue is not a functioning business; it is a listed shell. Net profit fell 206.45%, with a ₹1 Cr loss, and ROCE is -13.69%. The Piotroski F-score of 2/9 screams financial distress. I cannot compute a P/E or book value because the data is missing, and a price of ₹30.99 with a market cap of ₹33 Cr gives me no margin of safety. The stock sits at the top of its 52-week range, ₹11.22 to ₹30.99, yet the business has deteriorated. This is not value investing; it is momentum speculation. Graham taught us to buy with a margin of safety, but there is no earnings, no cash flow, no dividend, and no disclosed debt/equity to anchor intrinsic value. In the hospital sector, a small asset play can sometimes be worthwhile, but only if book value and debt are known and the price is below liquidation value. Here we know almost nothing. The only conceivable reason to own this is a turnaround: new management, restructuring, or a fresh line of revenue. Until I see actual sales, improving margins, and positive returns on capital, this is a pass. I would rather lose an opportunity than lose capital. As I always say, the first rule is don't lose money; the second rule is don't forget the first. Global Longlife is a dangerous speculation, not an investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer